Uganda Health News API

{
    "totalArticles": 1158,
    "articles": [
        {
            "id": "577ce386f007b7646c14650fa372d035",
            "title": "Multiple Sclerosis Risk May Start Before Birth",
            "description": "Maternal diabetes, birthweight may play roles",
            "content": "Prenatal and perinatal factors were tied to multiple sclerosis (MS) in offspring, a Norwegian cohort study showed.\nPrenatal exposure to maternal diabetes was associated with a doubled risk of developing MS in adulthood (HR 2.15, 95% CI 1.37-3.37), re... [3760 chars]",
            "url": "https://www.medpagetoday.com/neurology/multiplesclerosis/119391",
            "image": "https://assets.medpagetoday.net/media/images/119xxx/119391.jpg",
            "publishedAt": "2026-01-12T20:58:54Z",
            "lang": "en",
            "source": {
                "id": "572d25e23e12ec1560e8ee1884a7057a",
                "name": "MedPage Today",
                "url": "https://www.medpagetoday.com"
            }
        },
        {
            "id": "aad02e0dddfefbf37928943c7957f9eb",
            "title": "1 benefits fade two years after stopping medication",
            "description": "A study has found that patients who stop taking weight loss medications will see the beneficial effects disappear within two years.",
            "content": "A large analysis of previous studies has found that patients who stop taking weight loss medications will see the beneficial effects disappear within two years, causing weight and health issues to reappear.\nResearchers reviewed data on 9,341 obese or... [2415 chars]",
            "url": "https://www.drugdiscoverytrends.com/study-finds-glp-1-benefits-fade-two-years-after-stopping-medication/",
            "image": "https://www.drugdiscoverytrends.com/wp-content/uploads/2025/11/Screenshot-2025-11-03-152750.png",
            "publishedAt": "2026-01-12T18:51:39Z",
            "lang": "en",
            "source": {
                "id": "6836ee89a694be6670174fb2572a5761",
                "name": "drugdiscoverytrends.com",
                "url": "https://www.drugdiscoverytrends.com"
            }
        },
        {
            "id": "bb34f980802e95b0784053df2f8887c0",
            "title": "Hacking Cancer’s Survival Code",
            "description": "Northwestern professor Vadim Backman, who teaches in the McCormick School of Engineering and the Feinberg School of Medicine, is director of the University’s Center for Physical Genomics and Engineering. Backman and his team used chromatin organization, computational modeling and the FDA-approved drug celecoxib to block cancer cells’ ability to adapt, thereby increasing chemotherapy’s effectiveness in a model of ovarian cancer.",
            "content": "Cancer’s defining trait is its relentless ability to survive — even against attacks from the immune system and harsh medical treatments.\nNorthwestern biomedical engineers have developed a first-of-its-kind strategy that prevents cancer cells from evo... [3564 chars]",
            "url": "https://magazine.northwestern.edu/discovery/vadim-backman-center-for-physical-genomics-and-engineering-cancer-treatment-chromatin-celecoxib-chemotherapy",
            "image": "https://magazine.northwestern.edu/assets/2026/Winter/Discovery-Backman__FocusFillWyItMC4zMiIsIi0wLjA0IiwxMjAwLDYzMF0.gif",
            "publishedAt": "2026-01-12T16:11:11Z",
            "lang": "en",
            "source": {
                "id": "3f39bf2551ca017b17727a0c4cd493c9",
                "name": "Northwestern Magazine",
                "url": "https://magazine.northwestern.edu"
            }
        }
    ]
}